Immune profiling identifies CD161+CD127+CD8+ T cells as a predictive biomarker for Anti-PD-L1 therapy response in the SCLC-I subtype
The SCLC-I subtype exhibited a distinct immune profile characterized by enrichment of CD161<sup>+</sup>CD127<sup>+</sup>CD8<sup>+</sup> T cells in both peripheral blood and tumor tissue, which was associated with PFS following anti-PD-L1 therapy. These findings highlight the significance of subtype-specific immune profiling and the potential of CD161<sup>+</sup>CD127<sup>+</sup>CD8<sup>+</sup> T cells as a predictive biomarker to guide precision immunotherapy in ES-SCLC.
Authors
- Zhi‐gang Cai
- Jianya Zhou (ORCID: https://orcid.org/0000-0001-8196-0166)
- Jingjing Qu
- Binggen Wu
- Jianying Zhou (ORCID: https://orcid.org/0000-0002-8924-935X)
- Lixiong Ying
- C. Xie
- Lijun Chen (ORCID: https://orcid.org/0000-0001-9374-6466)
- Bo Wang (ORCID: https://orcid.org/0000-0002-4834-4916)
- Jing Zheng (ORCID: https://orcid.org/0000-0001-7696-9991)
- Wenjia Sun
- Qian Shen (ORCID: https://orcid.org/0000-0002-4097-6775)
- Yuekang Li
Institutions
- Zhejiang Hospital (CN)
- Zhejiang Center for Disease Control and Prevention (CN)
- First Affiliated Hospital Zhejiang University (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1186/s12967-025-06724-8
- Citations
- 1
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Natural Science Foundation of Zhejiang Province